Compare Gilead Sciences, Inc. (GILD) vs HP Inc (HPQ) Price & Performance

Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.

Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.

HPQ trades at $30.2, down 6.33% on the day, amid concerns over a projected mid-single-digit PC sales decline in 2027. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels are mixed. Fundamentally, HPQ maintains solid profitability with a 4.14% net margin and attractive valuation at a P/E of 12.38 and P/S of 0.51. Recent earnings beats highlight operational strength, but negative shareholder equity and high liabilities pose balance sheet risks.

The outlook is cautious; while HPQ's dividend yield of 3.82% and consistent cash flow provide income appeal, near-term headwinds from PC market softness and competitive pressures may limit upside. Analyst consensus is mixed with a $25.75 price target below current levels, suggesting limited near-term growth potential. Investors should weigh stable cash generation against cyclical industry risks and elevated debt.